brainQr Therapeutics is developing next-generation therapies for major human diseases by targeting disordered proteins, a vast and previously largely undruggable class of biomolecules. Our mission is to harness cutting-edge scientific innovation to pioneer novel treatment strategies that address urgent unmet medical needs.

brainQr's lead program focuses on a first-in-class oral brain-penetrant small molecule designed to stabilize healthy Tau protein. This groundbreaking approach aims to prevent tau misfolding and spreading at its earliest stage, effectively stopping Alzheimer’s disease progression before irreversible neuronal damage occurs; think of it as statin for the brain - preventive, safe and upstream of current therapies.

• Markus Zweckstetter